Literature DB >> 32929996

Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association.

James E Tisdale, Mina K Chung, Kristen B Campbell, Muhammad Hammadah, Jose A Joglar, Jacinthe Leclerc, Bharath Rajagopalan.   

Abstract

Many widely used medications may cause or exacerbate a variety of arrhythmias. Numerous antiarrhythmic agents, antimicrobial drugs, psychotropic medications, and methadone, as well as a growing list of drugs from other therapeutic classes (neurological drugs, anticancer agents, and many others), can prolong the QT interval and provoke torsades de pointes. Perhaps less familiar to clinicians is the fact that drugs can also trigger other arrhythmias, including bradyarrhythmias, atrial fibrillation/atrial flutter, atrial tachycardia, atrioventricular nodal reentrant tachycardia, monomorphic ventricular tachycardia, and Brugada syndrome. Some drug-induced arrhythmias (bradyarrhythmias, atrial tachycardia, atrioventricular node reentrant tachycardia) are significant predominantly because of their symptoms; others (monomorphic ventricular tachycardia, Brugada syndrome, torsades de pointes) may result in serious consequences, including sudden cardiac death. Mechanisms of arrhythmias are well known for some medications but, in other instances, remain poorly understood. For some drug-induced arrhythmias, particularly torsades de pointes, risk factors are well defined. Modification of risk factors, when possible, is important for prevention and risk reduction. In patients with nonmodifiable risk factors who require a potentially arrhythmia-inducing drug, enhanced electrocardiographic and other monitoring strategies may be beneficial for early detection and treatment. Management of drug-induced arrhythmias includes discontinuation of the offending medication and following treatment guidelines for the specific arrhythmia. In overdose situations, targeted detoxification strategies may be needed. Awareness of drugs that may cause arrhythmias and knowledge of distinct arrhythmias that may be drug-induced are essential for clinicians. Consideration of the possibility that a patient's arrythmia could be drug-induced is important.

Entities:  

Keywords:  AHA Scientific Statements; Brugada syndrome; atrial fibrillation; bradycardia; tachycardia; tachycardia, atrioventricular nodal reentry; tachycardia, ventricular; torsades de pointes

Year:  2020        PMID: 32929996     DOI: 10.1161/CIR.0000000000000905

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  24 in total

Review 1.  Certain beta blockers (e.g., bisoprolol) may be reevaluated in hypertension guidelines for patients with left ventricular hypertrophy to diminish the ventricular arrhythmic risk.

Authors:  Goran Koracevic; Milovan Stojanovic; Dragan Lovic; Marija Zdravkovic; Dejan Sakac
Journal:  J Hum Hypertens       Date:  2021-03-02       Impact factor: 3.012

2.  A novel wireless ECG system for prolonged monitoring of multiple zebrafish for heart disease and drug screening studies.

Authors:  Tai Le; Jimmy Zhang; Anh H Nguyen; Ramses Seferino Trigo Torres; Khuong Vo; Nikil Dutt; Juhyun Lee; Yonghe Ding; Xiaolei Xu; Michael P H Lau; Hung Cao
Journal:  Biosens Bioelectron       Date:  2021-11-16       Impact factor: 10.618

3.  Association of Sinoatrial Node Radiation Dose With Atrial Fibrillation and Mortality in Patients With Lung Cancer.

Authors:  Kyung Hwan Kim; Jaewon Oh; Gowoon Yang; Joongyo Lee; Jihun Kim; Seo-Yeon Gwak; Iksung Cho; Seung Hyun Lee; Hwa Kyung Byun; Hyo-Kyoung Choi; Jinsung Kim; Jee Suk Chang; Seok-Min Kang; Hong In Yoon
Journal:  JAMA Oncol       Date:  2022-09-22       Impact factor: 33.006

Review 4.  Cardiovascular Safety and Effectiveness of Bisphosphonates: From Intervention Trials to Real-Life Data.

Authors:  Chiara Delli Poggi; Maria Fusaro; Maria Cristina Mereu; Maria Luisa Brandi; Luisella Cianferotti
Journal:  Nutrients       Date:  2022-06-07       Impact factor: 6.706

5.  Editorial: A Changing Epidemic and the Rise of Opioid-Stimulant Co-Use.

Authors:  Saeed Ahmed; Zouina Sarfraz; Azza Sarfraz
Journal:  Front Psychiatry       Date:  2022-07-06       Impact factor: 5.435

Review 6.  Anti-Arrhythmic Effects of Sodium-Glucose Co-Transporter 2 Inhibitors.

Authors:  Yuling Jing; Ruixue Yang; Wen Chen; Qiang Ye
Journal:  Front Pharmacol       Date:  2022-06-24       Impact factor: 5.988

7.  Analysis of Respiratory Fluoroquinolones and the Risk of Sudden Cardiac Death Among Patients Receiving Hemodialysis.

Authors:  Magdalene M Assimon; Patrick H Pun; Lily Chin-Hua Wang; Sana M Al-Khatib; M Alan Brookhart; David J Weber; Wolfgang C Winkelmayer; Jennifer E Flythe
Journal:  JAMA Cardiol       Date:  2022-01-01       Impact factor: 30.154

Review 8.  Stroke in SARS-CoV-2 Infection: A Pictorial Overview of the Pathoetiology.

Authors:  Saeideh Aghayari Sheikh Neshin; Shima Shahjouei; Eric Koza; Isabel Friedenberg; Faezeh Khodadadi; Mirna Sabra; Firas Kobeissy; Saeed Ansari; Georgios Tsivgoulis; Jiang Li; Vida Abedi; Donna M Wolk; Ramin Zand
Journal:  Front Cardiovasc Med       Date:  2021-03-29

9.  Electrical storm after correction of an uncomplicated congenital atrial septal defect in an adult: a case report.

Authors:  Ying Liang; Feilong Hei; Yulong Guan
Journal:  BMC Cardiovasc Disord       Date:  2021-07-22       Impact factor: 2.298

10.  Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors and Sudden Cardiac Arrest and Ventricular Arrhythmia: Population-Based Cohort Studies.

Authors:  Ghadeer K Dawwas; Sean Hennessy; Colleen M Brensinger; Rajat Deo; Warren B Bilker; Samantha E Soprano; Neil Dhopeshwarkar; James H Flory; Zachary T Bloomgarden; Christina L Aquilante; Stephen E Kimmel; Charles E Leonard
Journal:  Clin Pharmacol Ther       Date:  2021-08-17       Impact factor: 6.903

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.